183 related articles for article (PubMed ID: 23013664)
1. PET/CT and choline: diagnosis and staging.
Farsad M; Schwarzenböck S; Krause BJ
Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):343-53. PubMed ID: 23013664
[TBL] [Abstract][Full Text] [Related]
2. Restaging prostate cancer patients with biochemical failure with PET/CT and radiolabeled choline.
Giovacchini G; Breeuwsma AJ
Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):354-66. PubMed ID: 23013665
[TBL] [Abstract][Full Text] [Related]
3. Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer.
Schwarzenböck S; Souvatzoglou M; Krause BJ
Theranostics; 2012; 2(3):318-30. PubMed ID: 22448198
[TBL] [Abstract][Full Text] [Related]
4. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates.
Krause BJ; Souvatzoglou M; Treiber U
Urol Oncol; 2013 May; 31(4):427-35. PubMed ID: 21388835
[TBL] [Abstract][Full Text] [Related]
5. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.
Farsad M; Schiavina R; Castellucci P; Nanni C; Corti B; Martorana G; Canini R; Grigioni W; Boschi S; Marengo M; Pettinato C; Salizzoni E; Monetti N; Franchi R; Fanti S
J Nucl Med; 2005 Oct; 46(10):1642-9. PubMed ID: 16204714
[TBL] [Abstract][Full Text] [Related]
6. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer.
Picchio M; Giovannini E; Crivellaro C; Gianolli L; di Muzio N; Messa C
Radiother Oncol; 2010 Sep; 96(3):347-50. PubMed ID: 20708811
[TBL] [Abstract][Full Text] [Related]
7. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
[TBL] [Abstract][Full Text] [Related]
8. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.
Budiharto T; Joniau S; Lerut E; Van den Bergh L; Mottaghy F; Deroose CM; Oyen R; Ameye F; Bogaerts K; Haustermans K; Van Poppel H
Eur Urol; 2011 Jul; 60(1):125-30. PubMed ID: 21292388
[TBL] [Abstract][Full Text] [Related]
11. Improved detection of localized prostate cancer using co-registered MRI and 11C-acetate PET/CT.
Jambor I; Borra R; Kemppainen J; Lepomäki V; Parkkola R; Dean K; Alanen K; Arponen E; Nurmi M; Aronen HJ; Minn H
Eur J Radiol; 2012 Nov; 81(11):2966-72. PubMed ID: 22342610
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.
Testa C; Schiavina R; Lodi R; Salizzoni E; Corti B; Farsad M; Kurhanewicz J; Manferrari F; Brunocilla E; Tonon C; Monetti N; Castellucci P; Fanti S; Coe M; Grigioni WF; Martorana G; Canini R; Barbiroli B
Radiology; 2007 Sep; 244(3):797-806. PubMed ID: 17652190
[TBL] [Abstract][Full Text] [Related]
13. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.
Martorana G; Schiavina R; Corti B; Farsad M; Salizzoni E; Brunocilla E; Bertaccini A; Manferrari F; Castellucci P; Fanti S; Canini R; Grigioni WF; D'Errico Grigioni A
J Urol; 2006 Sep; 176(3):954-60; discussion 960. PubMed ID: 16890665
[TBL] [Abstract][Full Text] [Related]
14. Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging.
Watanabe H; Kanematsu M; Kondo H; Kako N; Yamamoto N; Yamada T; Goshima S; Hoshi H; Bae KT
J Magn Reson Imaging; 2010 May; 31(5):1151-6. PubMed ID: 20432351
[TBL] [Abstract][Full Text] [Related]
15. PET-CT for treatment planning in prostate cancer.
Picchio M; Crivellaro C; Giovacchini G; Gianolli L; Messa C
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):245-68. PubMed ID: 19293771
[TBL] [Abstract][Full Text] [Related]
16. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
17. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions.
Li X; Liu Q; Wang M; Jin X; Liu Q; Yao S; Liu S; Li J
Clin Nucl Med; 2008 Oct; 33(10):671-6. PubMed ID: 18806565
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging.
Nitsch S; Hakenberg OW; Heuschkel M; Dräger D; Hildebrandt G; Krause BJ; Schwarzenböck SM
J Nucl Med; 2016 Oct; 57(Suppl 3):38S-42S. PubMed ID: 27694169
[TBL] [Abstract][Full Text] [Related]
19. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.
Picchio M; Messa C; Landoni C; Gianolli L; Sironi S; Brioschi M; Matarrese M; Matei DV; De Cobelli F; Del Maschio A; Rocco F; Rigatti P; Fazio F
J Urol; 2003 Apr; 169(4):1337-40. PubMed ID: 12629355
[TBL] [Abstract][Full Text] [Related]
20. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration.
Souvatzoglou M; Weirich G; Schwarzenboeck S; Maurer T; Schuster T; Bundschuh RA; Eiber M; Herrmann K; Kuebler H; Wester HJ; Hoefler H; Gschwend J; Schwaiger M; Treiber U; Krause BJ
Clin Cancer Res; 2011 Jun; 17(11):3751-9. PubMed ID: 21493868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]